Myeloproliferative Neoplasms News

A bedside visual art intervention improved mood while reducing pain and anxiety among patients with hematologic malignancies, according to study results.

Rates of therapy-related myelodysplastic syndrome and acute myeloid leukemia have risen significantly in the modern era following chemotherapy for nearly all solid tumor cancer types, according to results of a population-based cohort study published in JAMA Oncology.

The FDA today issued new guidance to help drug developers select endpoints for marketing applications with the goal of advancing the efficient development of cancer drugs and biologics.

SAN DIEGO — Higher gut microbial diversity was associated with improved survival in a multinational cohort of patients undergoing hematopoietic stem cell transplantation, according to findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Prior cancer treatment with chemotherapy, radiation or both was associated with an increased risk for subsequent acute lymphoblastic leukemia, according to findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — ASH honored three practitioners as Choosing Wisely champions at ASH Annual Meeting and Exhibition for successfully implementing programs at their institutions that reduced the use of unneeded hematology tests and treatments.

SAN DIEGO — A personalized risk prediction model developed using machine learning showed utility as a predictive and prognostic tool among patients with myelodysplastic syndrome, according to findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Luspatercept significantly reduced the transfusion burden compared with placebo among patients with anemia due to myelodysplastic syndrome, according to results of a randomized, double-blind, placebo-controlled phase 3 study presented during the plenary session of ASH Annual Meeting and Exposition.

NEW YORK — Ruxolitinib has dramatically improved the care of patients with myelofibrosis, but new treatment strategies for patients who progress on the drug or discontinue therapy are desperately needed, according to a presenter at Chemotherapy Foundation Symposium.

Four individuals have been elected to American Society of Hematology’s executive committee.